Quest Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Firm's Nichols Institute develops HIV-I genotyping test intended to identify gene mutation patterns associated with drug resistance and assist in optimal drug therapy selection for individual HIV patients, the firm states in an April 14 release. If a physician suspects drug resistance, the test "can identify mutation patterns in the virus' genes, and point to which drugs are probably not working," states Gregory Critchfield, MD, Quest senior VP and chief medical and science officer. The test is "more robust" and more rapid than competing tests, the company maintains. It "takes advantage of the benefits of full gene sequencing, which enables detection of all gene mutations that occur in a gene," whereas "alternative diagnostic approaches, such as gene chip technology, can miss some gene mutations"
|
Firm's Nichols Institute develops HIV-I genotyping test intended to identify gene mutation patterns associated with drug resistance and assist in optimal drug therapy selection for individual HIV patients, the firm states in an April 14 release. If a physician suspects drug resistance, the test "can identify mutation patterns in the virus' genes, and point to which drugs are probably not working," states Gregory Critchfield, MD, Quest senior VP and chief medical and science officer. The test is "more robust" and more rapid than competing tests, the company maintains. It "takes advantage of the benefits of full gene sequencing, which enables detection of all gene mutations that occur in a gene," whereas "alternative diagnostic approaches, such as gene chip technology, can miss some gene mutations". |